US
Europe (English)
Chinese
Japanese-
次世代シークエンシング
-
RNA-Seq全ゲノムシーケンシングターゲットリシーケンシングとカスタム遺伝子パネルエクソームシーケンシングメタゲノミクスシーケンシング - 16S MetaVxアンプリコンシーケンシングバイオインフォマティクスソリューションシーケンシングのみ Sequencing-onlyHigh Throughput Gene Expression Screening NEWSingle-Cell SequencingCRISPR関連NGSアプリケーション空間的遺伝子発現解析 Stereo-seqOlinkプロテオミクス解析 NEWプラスミド全長シーケンス解析 Plasmid-EZ NEW
-
-
サンガーシーケンシング
-
精製テンプレート難解テンプレートシーケンシング大腸菌コロニーとファージ未精製PCRプレミアムサービス
-
-
人工遺伝子合成
-
標準遺伝子合成短納期遺伝子合成合成DNAライブラリーCRISPR構造体合成DNAクローニング部位特異的突然変異誘発mRNA 合成 NEW
-
-
分子遺伝学
-
cDNAとgDNA検証サービスフラグメント解析SNP変異解析酵母コロニーシーケンシング核酸抽出
-
-
プラスミドDNA精製
-
プラスミドDNA調製
-
-
GLP順守サービス
-
検証的シーケンシングSNP変異解析プラスミド精製核酸抽出
-
ハイスループットの遺伝子発現スクリーニング
次世代シークエンシングをベースとするAzenta Life Scienceのハイスループット遺伝子発現（HT-GEx）スクリーニングは、DRUG-Seqと同様、創薬と解析のための最適なアプローチです。マイクロアレイと異なり、短時間でバイアスのない3’遺伝子発現スクリーニングを提供し、標準的なRNAシークエンシングよりも抑えたコストで、細胞からデータまで、トランスクリプトームの解析を実現します。ライセートから直接解析を行うハイスループット遺伝子発現スクリーニングでは、RNAの精製が不要。時間とコストの両方を節減します。また、転写物の3’端のみ検出することで、必要なシークエンシングの深度を低減することが可能です。
Applications
Drug Discovery
Compound Treatment Phenotyping
CRISPR Treatment Phenotyping
Cell Response Screening
HIGH-THROUGHPUT GENE EXPRESSION SCREENING WORKFLOW
Technology Comparison
| Metric | HT-GEx Screening | mRNA-Seq | Total RNA-Seq | Iso-Seq |
| Reads/Sample | ~1-2M Reads | ~10-30M Reads | ~20-45M Reads | ~1-2M Reads |
| Min. Sample Size | 96/384 | 1 | 1 | 1 |
| Cost | $ | $$ | $$$ | $$$$ |
| Starting Material | Cell Lysate | >20ng Total RNA | >100ng Total RNA | >1ug Total RNA |
| Selection Method | Poly(A) + | Poly(A) + | rRNA - | Poly(A) + |
| Detection Level | 3' Tails of Genes | Poly(A) Transcript | All Transcript | Full-Length Poly(A) Transcript |
| Gene Expression | ||||
|
Variant Detection |
||||
| Alternative Splicing | ||||
| Transcriptome Assembly |
Suitable method | Preferred method | Not a suitable method
Deliverables
Standard Deliverables
- FASTQ files
- Quality summary report
Advanced Analysis
(In addition to standard deliverables)
- UMI extraction, mapping, counting, and transformation
- Normalization
- Differential gene expression and clustering by compound/treatment
Custom bioinformatics analysis and reports are available. Please contact us about how we can customize the analysis to answer your biological question.
Features & Benefits
Fast Turnaround Times
Starting at just 2 weeks for quick target discovery
High-Throughput Capacity
To rapidly scale up pilot or discovery projects
Superior Data Quality
Exceeding manufacturers’ benchmarks
High-throughput, cell-to-data solution for compound screening
Low-cost, unbiased coverage for use in selection of drug candidates
Receive detailed expression data for each well across multiple 96- or 384-well plates
Free technical consultation and customer support from Ph.D.-level project managers and lab scientists
Webinar Series | Advancing Transcriptomics: Gene Expression Screening, Single-Cell RNA-Seq, and Beyond
With this two-part webinar series, go beyond traditional transcriptomics and learn about the various NGS approaches available for gene expression analysis. In part 1, we take an in-depth look at various gene expression approaches, including RNA-Seq, single-cell RNA-Seq, digital spatial profiling, and more. In part 2, we explore the data generated from these approaches and how they can complement each other and confirm findings.
Tech Note | Achieving Phenotypic Profiling for Rapid Drug Discovery with High-Throughput Gene Expression Screening
High-throughput technologies are critical in performing phenotypic profiling for drug discovery applications. In this tech note, Azenta Life Sciences discusses the challenges associated with traditional approaches, such as microarrays and RNA sequencing, and offers an optimized assay to achieve high-quality phenotypic profiling at a reduced cost for rapid drug discovery.
NGS Platforms
Azenta is a certified service provider for Illumina and other cutting-edge NGS platforms. For information on our NGS platforms, as well as recommended configurations of your projects, please visit the NGS Platforms page. Azenta does not guarantee data output or quality for sequencing-only projects.
